Regulatory Expert Appointed to Lead West Coast US Client Engagement for G&L Healthcare Advisors
MADISON, NJ / ACCESSWIRE / June 3, 2024 / G&L Healthcare Advisors is delighted to announce that Richard Edmunds, a...
Month: June 2024
Psirenity Health Adds Key Executive to its Experienced and Innovative Leadership Team
Oakville, Ontario--(Newsfile Corp. - June 3, 2024) - Psirenity Health is incredibly pleased to announce that Mr. Andrew Macdonald has...
Novo Integrated Sciences and RC Consulting Consortium Group Amend $70,000,000 Promissory Note
BELLEVUE, Wash.--(BUSINESS WIRE)--$NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today the Company and RC Consulting...
KindlyMD Announces Closing of $6.8 Million Initial Public Offering
SALT LAKE CITY, UT / ACCESSWIRE / June 3, 2024 / KindlyMD, Inc. (NASDAQ:KDLY)(NASDAQ:KDLYW) ("KindlyMD" or the "Company"), a patient-first...
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to...
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial...
RadiusXR Achieves ISO 13485 and MDSAP Certifications, Announces Expansion into Canadian Market
PLEASANTON, Calif.--(BUSINESS WIRE)--#Ophthalmology--RadiusXR, a leading innovator in digital health technology, is proud to announce that it has received ISO 13485...
Scryb Applauds New Bipartisan $32B Roadmap for AI Policy from U.S. Senate; Driving the Market for Scryb’s AI Compliance Solution
Toronto, Ontario--(Newsfile Corp. - June 3, 2024) - Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) (FSE: EIY) (Scryb'' or the "Company") is...
MedTech Outlook 2024 for Latin America Released
MIAMI, FL / ACCESSWIRE / June 3, 2024 / Global Health Intelligence (GHI), the leading healthcare data analytics provider in...
Unleashing the Power of Men’s Health: Whittier Street Health Center to Shine Spotlight on Equity and Access
Critical conversations about men's physical, mental, and emotional well-beingBOSTON, MA / ACCESSWIRE / June 3, 2024 / Whittier Street Health...
Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology
ALLEN, TX / ACCESSWIRE / June 3, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") is thrilled to announce that...
Monogram Technologies to Host Investor and Analyst Tour at its Headquarters in Austin, Texas, on Thursday, June 20th, 2024
Management to Showcase Product Demonstration of mBôs Precision Robotic Surgical System and mVision Technologies AUSTIN, TX / ACCESSWIRE / June...
Aptevo Participating in the BIO International Convention
SEATTLE, WA / ACCESSWIRE / June 3, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing...
CNS Pharmaceuticals Announces Reverse Stock Split
HOUSTON, TX / ACCESSWIRE / June 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
Modular Medical Announces Addition to the Russell Microcap(R) Index
SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery...
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced...
Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year
ORLANDO, FL / ACCESSWIRE / June 3, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today reported Q1 revenues of $408,532 emphasizing its...
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Media Release COPENHAGEN, Denmark; June 3, 2024 Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in...
BioPharmaSpec Announces Major Investments in Mass Spectrometry and Related Instrumentation
The state-of-the-art instrumentation will support and accelerate BioPharmaSpec’s clients’ efforts in successful biologics product developmentMALVERN, Pa. and ST. SAVIOUR, Jersey,...
Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting
Company presents results from in vivo studies of PT-CD16VS, a genetically modified allogeneic cell therapy derived from human placental circulating...